Changchun An1,2, Wang Jing2,3, Yan Zhang4, Sujing Liu5, Haiyong Wang2, Kunli Zhu2, Li Kong2, Hongbo Guo6, Hui Zhu2. 1. School of Medicine & Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan, Shandong Province, China. 2. Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong Province, China. 3. Department of Radiation Oncology, the First Affiliated Hospital to Zhengzhou University, Zhengzhou, Henan Province, China. 4. Department of Medical Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong Province, China. 5. Department of Radiation Oncology, Yantai Yuhuangding Hospital, Affiliated Hospital Medical College of Qingdao University, Yuhuangding Rd. 20, Yantai, Shandong Province, China. 6. Department of Thoracic Surgery, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong Province, China.
Abstract
AIM: To evaluate the effect of thoracic radiation therapy (TRT) in elderly patients (aged ≥65 years) with extensive-stage small-cell lung cancer (ES-SCLC). PATIENTS & METHODS: This study reviewed the records of 118 elderly patients with ES-SCLC (all with distant metastasis) through January 2006-December 2013. The patients were divided into either a chemotherapy (ChT)/TRT-combination group or a ChT-alone group. RESULTS: The median survival time and 3-year overall survival rates in the ChT/TRT group were significantly higher than those in the ChT-alone group (17.0 vs 11.7 months; 18.1 vs 14.9%; p = 0.014). The 3-year overall survival rates in patients who received prophylactic cranial irradiation were also higher than the rates in patients who did not receive prophylactic cranial irradiation (18.1 vs 5.1%; p = 0.708). CONCLUSION: TRT combined with ChT could provide a survival benefit to elderly patients with ES-SCLC.
AIM: To evaluate the effect of thoracic radiation therapy (TRT) in elderly patients (aged ≥65 years) with extensive-stage small-cell lung cancer (ES-SCLC). PATIENTS & METHODS: This study reviewed the records of 118 elderly patients with ES-SCLC (all with distant metastasis) through January 2006-December 2013. The patients were divided into either a chemotherapy (ChT)/TRT-combination group or a ChT-alone group. RESULTS: The median survival time and 3-year overall survival rates in the ChT/TRT group were significantly higher than those in the ChT-alone group (17.0 vs 11.7 months; 18.1 vs 14.9%; p = 0.014). The 3-year overall survival rates in patients who received prophylactic cranial irradiation were also higher than the rates in patients who did not receive prophylactic cranial irradiation (18.1 vs 5.1%; p = 0.708). CONCLUSION: TRT combined with ChT could provide a survival benefit to elderly patients with ES-SCLC.
Authors: Michael Stokes; Noami Berfeld; Alicia Gayle; Andrew Descoteaux; Oscar Rohrmoser; April Franks Journal: Medicine (Baltimore) Date: 2022-07-01 Impact factor: 1.817